SCHEMBL5934592

SCHEMBL5934592

CC(C)(C)c1cccc(NC(=O)c2ccc(-c3cccc(Cl)c3)nc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 1/20 0.55
▸ HDAC8 Q9BY41 1/20 0.55
▸ HDAC6 Q9UBN7 1/20 0.55
▸ P4HTM Q9NXG6 1/20 0.54
▸ P2RX1 P51575 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C9 P11712 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ KCNK9 Q9NPC2 1/20 0.48
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ CNR2 P34972 1/20 0.46
▸ PPARG P37231 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5934188 0.90 HDAC3 (0.56) HDAC3HDAC8HDAC6P4HTMP2RX1
SCHEMBL5934471 0.87 MEN1 (0.57) HDAC3HDAC8HDAC6KDM4EMEN1
SCHEMBL5934381 0.87 HPGDS (0.55) HDAC3HDAC8HDAC6ALDH1A1MEN1
SCHEMBL5934657 0.86 HDAC8 (0.54) HDAC3HDAC8HDAC6P2RX1ALDH1A1
SCHEMBL5934639 0.85 HDAC8 (0.53) HDAC3HDAC8HDAC6ALDH1A1KDM4E
SCHEMBL5934224 0.85 TP53 (0.55) HDAC3HDAC8HDAC6ALDH1A1KDM4E
SCHEMBL5934585 0.85 HDAC3 (0.55) HDAC3HDAC8HDAC6ALDH1A1MEN1
SCHEMBL5934416 0.84 HDAC3 (0.57) HDAC3HDAC8HDAC6ALDH1A1MEN1
SCHEMBL5934642 0.84 NR1H4 (0.54) HDAC3HDAC8HDAC6ALDH1A1KDM4E
SCHEMBL2303956 0.83 KMT2A (0.66) HDAC3HDAC8HDAC6P4HTMP2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575918-A2 SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2005-09-21 — — EP claimed
WO-2004056774-A2 SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-07-08 — — WO claimed
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues NEUROGEN CORPORATION (US) 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100245-A1 Substituted biphenyl-4-carboxylic acid arylamide analogues HCAR2, AHR, HCAR3 HDAC3 424/4885HDAC8 740/4885HDAC6 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback